Using the cutoff of 7.5% IFN-γ+ naïve γδT in total γδT cells, we found that 86% of the CML patients with >7.5% IFN-γ+ naïve γδT achieved MR4.0 in 5 years, and only 63% of the CML patients with ≤7.5% of IFN-γ+ naïve γδT cells reached DMR in 5 years. The gene discussed is IFNG; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.